Novimmune is a drug discovery and development company focused on the creation of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

To date, Novimmune has generated several therapeutic antibodies designed to treat immune-related disorders and is now poised to enter the immune-oncology space with new products that aim to fight cancer.

The pipeline is a balance of preclinical and clinical compounds, specific for clinically validated and novel targets. Each of these portfolio products has the potential of becoming a medicine for multiple medical conditions due to the intrinsic mechanism of action.

Five of these compounds are currently in early clinical development with the three most advanced in clinical Phase II. In addition, Novimmune has initiated two internal, bispecific antibody programs against Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, as well as other oncology targets to yet be announced.

The company has also been purposefully targeting a number of orphan drug indications, with the express hope of eventually providing safe and effective treatment options to some of the often neglected populations suffering from rare diseases.

Where the mechanism of action of a discovered antibody indicates broader applications or multiple indications, Novimmune has partnered the development of the compound with larger pharmaceutical companies. In 2010, for example, the company signed an exclusive partnering agreement to co-develop its NI-1401 compound with Genentech / Roche. That compound completed Phase I clinical trials in 2013.

In addition to these compounds, Novimmune has developed two unique and proprietary antibody generation platforms — a monoclonal antibody platform and a bispecific antibody platform — designed to streamline the identification, production, and characterization of fully-human antibodies. Novimmune makes these technology platforms available to create unique antibodies for outside pharmaceutical companies.

In 2009, Novimmune received the European Biotechnica Award in recognition of being the European biotechnology company with "the greatest future potential."

The company is based in the Plan-les-Ouates suburb of Geneva, Switzerland, and maintains strong ties to a number of academic research institutions, including the University of Geneva.

For more information,visit www.novimmune.com.